Jacqueline Kraveka to Eflornithine
This is a "connection" page, showing publications Jacqueline Kraveka has written about Eflornithine.
Connection Strength
1.147
-
Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 09 27; 8(1):14445.
Score: 0.638
-
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Nov; 5(11):e1616.
Score: 0.203
-
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 12 01; 147(11):3152-3159.
Score: 0.179
-
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246.
Score: 0.127